Every 8-K that Phio Pharmaceuticals Corp (PHIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PHIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHIO filings page.
Phio Pharmaceuticals Corp. reported financial results for the quarter ended June 30, 2026 and provided an update on its lead INTASYL®-based candidate PH-762. Research and development expenses for the quarter were $3.1 million, an increase of $2.0 million or 187%, driven mainly by nonclinical toxicology and CMC work on PH-762. General and administrative expenses were $1.2 million, slightly lower than the prior-year quarter, and quarterly net loss was $4.1 million compared with $2.2 million a year earlier.
As of June 30, 2026, Phio held $13.0 million in cash and cash equivalents versus $21.0 million at December 31, 2025, and management expects existing cash to fund planned operations into the second half of 2027. In April 2026 the company established an at the market equity offering program of up to $6.36 million. PH-762 completed a 22-patient Phase 1b intratumoral trial in skin cancers; final documentation is being prepared for FDA submission, and Phio intends to request an FDA meeting in the third quarter of 2026 to discuss next clinical steps. The company also initiated commercial-scale API production and a long-term non-clinical toxicology study expected to complete by year end, reported multiple new patent allowances in the United States, Canada and Japan, and appointed dermatologist and former FDA advisory committee member Dr. R. Todd Plott to its board.
Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, expanded its Board of Directors to six members effective July 20, 2026 and appointed R. Todd Plott, M.D., a board-certified dermatologist, as director until the 2026 annual meeting and as a member of the Governance Committee.
Dr. Plott brings more than 30 years of experience in dermatologic care, research and clinical trials, including service on the FDA Dermatologic and Ophthalmic Drug Advisory Committee from 2016 to 2021. He will enter into Phio’s standard indemnification agreement and receive standard non-employee director compensation, with no related-party arrangements reported.
The company reiterates its focus on its proprietary INTASYL siRNA gene-silencing platform and lead INTASYL compound PH-762, evaluated in a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical skin cancer treatment.
Phio Pharmaceuticals Corp. reported first quarter 2026 results and a business update centered on its lead cancer candidate PH-762. The Phase 1b intratumoral dose-escalation trial in skin cancers has completed enrollment with 22 patients, and final data analysis is underway ahead of a planned FDA submission in the second quarter of 2026.
Cash and cash equivalents were about $17.0 million as of March 31, 2026, down from roughly $21.0 million at year-end 2025, after 2025 equity financings and warrant exercises generated about $23.7 million and extended the cash runway into the first half of 2027. Phio also entered an at-the-market agreement allowing up to $6.36 million of additional common stock sales.
Research and development expenses rose to $2.8 million, a 215% increase from the prior-year quarter, mainly from clinical, CMC and toxicology work on PH-762. General and administrative expenses were $1.4 million, up 39%. Net loss widened to about $4.0 million, compared with roughly $1.8 million a year earlier.
Phio Pharmaceuticals Corp. entered into an at-the-market equity offering arrangement allowing it to sell up to $6,360,000 of common stock through H.C. Wainwright & Co. as sales agent. These shares are registered under an effective shelf registration statement and an accompanying prospectus supplement.
The sales agent will use commercially reasonable efforts to place shares under parameters Phio sets, and will earn a 3.0% commission on gross proceeds. Phio can suspend or terminate the program at any time and is not obligated to sell any shares. The company also agreed to reimburse up to $75,000 of the agent’s legal fees related to this arrangement.
Phio Pharmaceuticals reported that it has signed a cGMP drug product manufacturing services agreement with a U.S.-based manufacturer to produce its lead siRNA compound, PH-762, for clinical and potential commercial supply. PH-762 is being developed as an intratumoral treatment for cutaneous skin cancers.
In a Phase 1b trial of PH-762, 22 patients completed treatment across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events. The company reported an approximate 65% pathological response rate in cutaneous squamous cell carcinoma across all dosing cohorts, including 85% pathological response, or 6 of 7 patients, in the highest-dose cohort.
Phio indicated that engagement with the FDA on next-stage clinical development of PH-762 is targeted for the second quarter of 2026 and that its cash and cash equivalents are projected to sustain operations into the first half of 2027.
Phio Pharmaceuticals reported 2025 results showing progress in its lead cancer candidate PH-762 and a much stronger balance sheet. The Phase 1b dose-escalation trial of PH-762 completed enrollment with favorable safety, tolerability and pathology data, and the company plans an FDA submission on next-step study design in the second quarter of 2026.
During 2025, equity financings and warrant exercises generated approximately $23.7 million in net proceeds, lifting cash and cash equivalents to about $21.0 million at December 31, 2025, up from $5.4 million a year earlier and extending the cash runway into the first half of 2027. Research and development expenses rose 27% to $4.6 million and general and administrative expenses increased 23% to $4.6 million, reflecting expanded clinical activity and higher professional and compensation costs. Net loss widened to roughly $8.7 million, or $1.45 per share, compared with $7.2 million, or $9.08 per share, in 2024.
Phio Pharmaceuticals Corp. updated its employment agreement with President and Chief Executive Officer Robert J. Bitterman. The amendment increases his protection if he is terminated without cause or leaves for good reason, granting severance equal to twelve months of his base salary in those situations.
The amendment also raises Mr. Bitterman’s annual target bonus opportunity to 50% of his base salary, up from 40% under the prior agreement. The full terms are set out in the Second Amendment filed as an exhibit.
Phio Pharmaceuticals reported encouraging early results from its Phase 1b skin cancer trial of PH-762, its INTASYL gene-silencing compound. The Safety Monitoring Committee completed its planned review and found no dose-limiting toxicities or serious adverse events in 22 patients treated across five escalating dose cohorts.
In cutaneous squamous cell carcinoma, the company reports a 65% overall pathological response rate, with 13 of 20 patients responding, including 9 complete responses with 100% tumor clearance. At the highest dose cohort, 6 of 7 patients showed pathological response and 4 had complete responses.
Phio plans an FDA submission in the second quarter of 2026 to seek guidance on next-step trial design for PH-762. Manufacturing and CMC work is progressing, with API expected for a non-human primate study in March 2026 and cGMP material targeted for the second half of 2026.
PHIO Pharmaceuticals Corp. reported new clinical results from its intratumoral PH-762 dose-escalation trial in cutaneous carcinoma. The company highlighted that safety and tolerability were favorable across all dose levels. Pathology data showed a 70% overall response rate for squamous cell carcinomas, and among the 14 responders, 10 achieved 100% clearance of their tumors. These findings suggest PH-762 demonstrated meaningful anti-tumor activity in this early study while maintaining a manageable safety profile.
Phio Pharmaceuticals Corp. reported a development milestone for its investigational therapy PH-762. On December 23, 2025, the company announced that the U.S. Food and Drug Administration accepted its nonclinical protocol study design for PH-762, a key step that allows planned toxicology testing to move ahead. The company stated that this toxicology study is expected to begin in the first quarter of 2026, marking progress in advancing PH-762 through the preclinical development process.
PHIO Pharmaceuticals Corp. reported that it has completed enrollment in its ongoing Phase 1b clinical trial (NCT 06014086) of its INTASYL siRNA lead compound, PH-762. This means all planned participants have been enrolled and the study can now proceed using the full patient group for evaluation. The update was shared through a press release dated November 25, 2025, which is included as an exhibit to this report.
Phio Pharmaceuticals Corp. filed an 8-K announcing it reported financial results for the quarter ended September 30, 2025. The company furnished a related press release as Exhibit 99.1.
The disclosure under Item 2.02 is furnished, not filed, and will only be incorporated by reference into other filings if expressly stated. PHIO’s common stock trades on The Nasdaq Capital Market.
Phio Pharmaceuticals (PHIO) entered inducement agreements for warrant exercises and issued new warrants. Holders agreed to exercise 5,663,182 existing warrants, with portions exercised at $2.00 and $2.485, and 4,654,586 exercised or to be exercised at a reduced $2.05. In return, Phio issued unregistered Series A Warrants for up to 11,326,364 shares at $2.05, exercisable immediately for 24 months from the resale registration’s effective date.
Initial closings on November 4 and 6 generated approximately $12.6 million in gross proceeds, tied to 5,313,182 exercises and 10,626,364 new warrants issued. Additional closings are expected by November 18 for 350,000 more exercises and 700,000 additional new warrants. Phio expects total gross proceeds of about $13.4 million before fees and expenses, including $1,415,795.50 paid for the new warrants. The company will file a resale registration statement for the new warrant shares within 20 days and agreed to a brief issuance blackout. H.C. Wainwright serves as placement agent with cash fees and warrants as compensation.
Phio Pharmaceuticals (PHIO) reported early clinical signals in its Phase 1b dose‑escalation trial of INTASYL PH‑762 for cutaneous squamous cell carcinoma. The company announced Day 36 outcomes in the fifth and final dose cohort: 100% tumor clearance (Complete Response) in one patient, greater than 90% (Near Complete Response) in a second, and greater than 50% (Partial Response) in a third.
Phio also stated that the Safety Monitoring Committee issued a favorable review of safety data at the maximum dose. These updates come from the ongoing Phase 1b dose escalation study (NCT 06014086).
Phio Pharmaceuticals (PHIO) filed an 8-K announcing board changes. On October 31, 2025, Robert Ferrara resigned from the Board, the Compensation and Audit Committees, and as Lead Independent Director, effective immediately. The company states his decision to resign was not the result of any disagreement with the company.
Pursuant to the Governance Committee’s recommendation and following the resignation, the Board reduced its size from six to five members, leaving no vacancies. The company also announced the appointment of David Deming as Lead Independent Director in a press release issued on October 31, 2025, which is furnished as Exhibit 99.1.
Phio Pharmaceuticals Corp. reported results from its 2025 Annual Meeting of Stockholders held on September 11, 2025. Stockholders approved an amendment and restatement of the company’s 2020 Long Term Incentive Plan, increasing the number of common shares that may be issued under the plan by 950,000, bringing the total available for issuance to 1,023,017 shares.
All six director nominees were elected to serve until the 2026 annual meeting, and stockholders ratified Grant Thornton LLP as independent auditor for the year ending December 31, 2025. Investors also approved, on a non-binding basis, the compensation of named executive officers and selected “3 years” as the preferred frequency for future advisory votes on executive pay. The board has decided to hold these advisory votes once every three years, consistent with the stockholder preference. The company had 4,798,154 common shares outstanding as of the July 18, 2025 record date.
Phio Pharmaceuticals Corp. reported that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, which is scheduled for September 8-10, 2025. The company also noted that patients are now being treated in the 5th cohort of its ongoing Phase 1b clinical trial for skin cancer, indicating continued progression of this early-stage study.